Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...
PMLive2d
Biogen initiates phase 3 study of felzartamab in kidney transplant patients
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
GlobalData on MSN3d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
Pharmabiz2d
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Business Insider4d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
"I am pleased to see Biogen enroll the first patient in the Phase 3 TRANSCEND study of felzartamab in AMR and look forward to the trial’s continued enrollment.” TRANSCEND is a two-part ...
Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...
Nasdaq4d
Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
"I am pleased to see Biogen enroll the first patient in the Phase 3 TRANSCEND study of felzartamab in AMR and look forward to the trial’s continued enrollment.” TRANSCEND is a two-part ...
Zacks.com on MSN3d
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.